StreetInsider.com News Articles

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights

Thu, 02 Apr 2026 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.

2025 business and operational highlights

The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.

Full year 2025 financial review

As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million.

The Company projects that its existing cash and cash equivalents should be sufficient

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (“Celyad” or the “Company”), today announced the acquisition by CellProthera of C-Cathez®, the transendocardial catheter originally developed by Celyad Oncology. The acquisition is a decisive step for CellProthera as it prepares to enter Phase 3 clinical trial, with the transendocardial catheter as a cornerstone of its therapeutic approach, enabling targeted delivery of stem cells directly into damaged cardiac tissue. The transaction relates to all intellectual property rights and associated technical documentation.

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology Announces the Sale of C-CATHez ® Catheter

Thu, 12 Feb 2026 01:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million

Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Tue, 25 Nov 2025 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated November 20, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed above the 65% threshold, holding 49,050,641 voting rights, i.e. 67.77% of Celyad Oncology’s voting rights.

Content of the Notification:

Reason

Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Tue, 25 Nov 2025 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Content of the Notification:

Reason

Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Tue, 25 Nov 2025 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Content of the Notification:

Reason

Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Tue, 25 Nov 2025 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Content of the Notification:

Reason

Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Tue, 25 Nov 2025 13:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Content of the Notification:

Reason